Table 3 Follow-up details of subjects who had further treatment after the phase Ib study
From: Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
Patient | Prior therapies | Response to prior line | Duration of response (months) | No. of AZA-vorinostat cycles | Subsequent therapies | Time between combination to subsequent therapy (days) | Response to subsequent therapies | TTP post-study (days) | OS post-study (days) | Survival status |
|---|---|---|---|---|---|---|---|---|---|---|
1 | RCHOP (×6) | CR | 40 | 3 | Veltuzumab with 90Y-epratuzumab | 14 | Significant clinical benefit | 115 | 682 | Dead |
2 | RCHOP (×6), VIPER (×3), BEAM, and ASCT | PD | NA | 4 | Oral PEP-C | 16 | Significant clinical benefit | 408 | 556 | Alive |
3 | CHOP + RT 10 years prior. De Angelis, RDICE (×3) | CR | 8 | 2 | Oral PEP-C | 18 | CR | 220 | 501 | Alive |
4 | RCHOP (×6), RDICE, RHCVAD (Bcycle) | PD | NA | 2 | Brentuximab + PEP-C (×4) | 2 | PD | 79 | 148 | Dead |
5 | RCHOP (×6), ESHAP (×3), lenalidomide, ibrutinib | PD | NA | 4 | RDICE (×3), ASCT | 11 | CR | 436 | 825 | Dead |
6 | RCHOP (×6), RDICE (×2), ibrutinib | PD | NA | 1 | Bendamustine (×1) | 1 | Significant clinical benefit | NA | 45 | Dead |
7 | RCHOP (×6), RICE (×2), R-Nav/Gem#1 | PD | NA | 1 | Bendamustine (×1) | 4 | NA | NA | 35 | Alive |